Kura Oncology (KURA) Climbs 40% Following Positive Preliminary Ziftomenib Combination Data in Acute Myeloid Leukemia

Visit StreetInsider.com at http://www.streetinsider.com/Momentum+Movers/Kura+Oncology+%28KURA%29+Climbs+40%25+Following+Positive+Preliminary+Ziftomenib+Combination+Data+in+Acute+Myeloid+Leukemia/22691693.html for the full story.